Opinion|Videos|January 31, 2025

Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

2

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.


Latest CME